Skip to main content
. Author manuscript; available in PMC: 2013 May 25.
Published in final edited form as: Immunity. 2012 Mar 29;36(5):847–856. doi: 10.1016/j.immuni.2012.02.012

Figure 2. IL-2 impairs GC B cell responses to influenza.

Figure 2

(A) B6 mice were infected with PR8 and treated with 30,000 U of human recombinant rIL-2 or PBS twice a day starting 3 days after infection. mLNs were obtained on day 10 after infection and cryosections were stained with anti-B220 (blue) and PNA (red) and analyzed by fluorescent microscopy. (B–C) Cells from the mLNs of mice treated with IL-2 or PBS were obtained on day 10 and the percentage of CD19+ B cells with a PNA+FAS+ GC phenotype was determined (B), and the number of GC B cells was calculated (C). Data are representative of four independent experiments (mean ± s.d of 5 mice per group). (D–E) Cells from mLN were obtained on day 10 after infection and GC B cells were identified by flow cytometry using an NP-tetramer. The percentage of NP-specific B cells with a PNA+FAS+ GC phenotype was determined (D) and the number of NP-specific PNA+FAS+ CD19+ B cells was calculated (E). Data are representative of three independent experiments (mean ± s.d of 5 mice per group). All P values were determined using a two-tailed Student´s t-test. See also Supp. Fig. 1.